A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.

One Kansas City priest is especially thankful he's able to continue his calling this American Heart Month, thanks to a new ...

We're just setting up a generation of people to move through life, having their cardiovascular events earlier and more severe ...

Without better prevention and early detection, the number of women living with cardiovascular disease will increase substantially in the next 25 years, the American Heart Association said.

Attention deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that affects how the brain develops ...

A psychoactive drug derived from an African plant could transform treatment for addiction and PTSD. Here’s why Tennessee ...

GSK has reached a near-$1bn deal to acquire 35Pharma, a Canadian biotech that develops drugs for heart and lung diseases, as ...

Dr. Sadiya Khan, Director, Center for Population Science and Aging, Northwestern Medicine, joins John Williams to talk about the public splash around weight loss medications and how they interact ...

BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.